# Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

> **NCT03088670** · PHASE3 · COMPLETED · sponsor: **SatRx LLC** · enrollment: 299 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Gosogliptin
- **DRUG:** Vildagliptin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03088670
- **Lead sponsor:** SatRx LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-23
- **Primary completion:** 2014-03-30
- **Final completion:** 2014-10-03
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088670, "Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03088670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*